CTI BioPharma Corp (CTIC) - Financial and Strategic SWOT Analysis Review

July 2021 | 45 pages | ID: C0EDD40F9B7EN
GlobalData

Abstracts

CTI BioPharma Corp (CTIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

CTI BioPharma Corp (CTI BioPharma) is a biopharmaceutical company that acquires, develops and commercializes novel therapies for a range of blood-related cancers. The company’s lead product, Pacritinib is intended for the treatment of patients with myeloproliferative diseases. Its product pipeline includes PACIFICA for the treatment of myelofibrosis patients with severe thrombocytopenia; PAC203 for the patients with ruxolitinib therapy failure; PRE-VENT for COVID-19; PERSIST 1 for all platelets count and PERSIST 2 for platelets counts less than thousand. The company has subsidiaries in the UK and the US. CTI BioPharma is headquartered in Seattle, Washington, the US.

CTI BioPharma Corp Key Recent Developments

Jun 01,2021: CTI BioPharma Reports First Quarter 2021 Financial Results
Apr 07,2021: CTI BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, Apr. 14
Mar 31,2021: CTI BioPharma Announces Pricing of its Public Offering of Common Stock and Preferred Stock
Mar 17,2021: CTI BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results
Mar 12,2021: CTI BioPharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 17, 2021

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

CTI BioPharma Corp - Key Facts
CTI BioPharma Corp - Key Employees
CTI BioPharma Corp - Key Employee Biographies
CTI BioPharma Corp - Major Products and Services
CTI BioPharma Corp - History
CTI BioPharma Corp - Company Statement
CTI BioPharma Corp - Locations And Subsidiaries
Head Office

SECTION 2 – COMPANY ANALYSIS

Company Overview
CTI BioPharma Corp - Business Description
CTI BioPharma Corp - Corporate Strategy
CTI BioPharma Corp - SWOT Analysis
SWOT Analysis - Overview
CTI BioPharma Corp - Strengths
CTI BioPharma Corp - Weaknesses
CTI BioPharma Corp - Opportunities
CTI BioPharma Corp - Threats
CTI BioPharma Corp - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
CTI BioPharma Corp, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jun 01, 2021: CTI BioPharma Reports First Quarter 2021 Financial Results
Apr 07, 2021: CTI BioPharma to Present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, Apr.
Mar 17, 2021: CTI BioPharma Reports Fourth Quarter and Full Year 2020 Financial Results
Mar 12, 2021: CTI BioPharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 17, 2021
Feb 25, 2021: CTI BioPharma to Present at the Cowen 41st Annual Health Care Conference on Thursday, Mar.
Nov 10, 2020: CTI BioPharma reports third quarter 2020 financial results
Aug 06, 2020: CTI BioPharma reports second quarter 2020 financial results
May 07, 2020: CTI BioPharma reports first quarter 2020 financial results
Mar 12, 2020: CTI BioPharma reports fourth quarter and full year 2019 financial results
Feb 03, 2020: CTI BioPharma announces proposed rights offering

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

CTI BioPharma Corp, Key Facts
CTI BioPharma Corp, Key Employees
CTI BioPharma Corp, Key Employee Biographies
CTI BioPharma Corp, Major Products and Services
CTI BioPharma Corp, History
CTI BioPharma Corp, Key Competitors
CTI BioPharma Corp, Ratios based on current share price
CTI BioPharma Corp, Annual Ratios
CTI BioPharma Corp, Annual Ratios (Cont...1)
CTI BioPharma Corp, Interim Ratios
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
CTI BioPharma Corp, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

CTI BioPharma Corp, Performance Chart (2016 - 2020)
CTI BioPharma Corp, Ratio Charts
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021